Corcept Therapeutics is climbing hard while short sellers refuse to blink — the stock has gained 31% in a month, yet short interest barely budged.
Options traders have flipped from defensive to outright bullish in a matter of days. The put/call ratio collapsed to 0.27, nearly 1.6 standard deviations below its 20-day mean of 0.51, and is at the lowest reading of the past year. Two weeks ago it sat comfortably above 0.60. That is a striking shift: the same crowd that was buying put protection through early May is now piling into calls as the stock approaches $60.36.
Short positioning tells a different story — and that divergence is the most interesting tension here. Short interest remains at 12.2% of free float, essentially flat on the week and only modestly lower than the 14.2% reading from late April. Sellers who covered after the Q1 earnings print on April 30 — which sent the stock up over 10% in a day — have largely been replaced. The borrow market offers no squeeze signal either: cost to borrow is a negligible 0.51% annualised, and availability is extraordinarily loose at 892%, meaning there are nearly nine shares available in the lending pool for every one already borrowed. There is no shortage of ammunition for new shorts. What's notable is that a 31% monthly rally has not driven even modest short covering — the remaining shorts are either hedges or genuinely convicted bears still in the name.
The Street has rapidly rerated. UBS upgraded to Buy on May 13, raising its target from $44 to $72 — the most significant shift of the recent cycle. Piper Sandler followed from Overweight with a target hike to $88, and HC Wainwright lifted to $75. The consensus is four Buys and one Hold, with a mean target of $79 — around 31% above current levels. Factor scores reinforce the bull case: EPS surprise ranks in the 92nd percentile of the universe, forward EPS growth is projected at roughly 68% year-over-year, and the ORTEX composite stock score has re-rated sharply from ~59 to 77.6 since the April results, driven almost entirely by a surge in the Growth (78) and Momentum (66) pillars. Value remains the weak link, with the P/E running at 64x and the EV/EBITDA near 26x — elevated but contracting from higher levels a month ago.
Insider activity adds a cautionary wrinkle to the bullish consensus. CEO Joseph Belanoff sold 40,000 shares at roughly $50 on May 1, banking just over $2 million. A chief-level officer, William Guyer, sold a further 20,000 shares at $51.83 on May 5. Both transactions came as the stock broke above levels where it had previously stalled, and neither was trivial in size. Set against that, director George Baker bought 100,000 shares in March at around $33 — a purchase now sitting on a near-90% gain — underscoring that the insider picture is mixed rather than uniformly cautious. Net insider activity over the past 90 days is a positive $13 million in value terms, but that figure is dominated by Baker's well-timed buy; recent direction from the executive suite is decidedly toward the exit.
Earnings history provides useful context without any predictive weight. The most recent print — April 30 — produced a 10.4% one-day gain and a 9.6% five-day gain: a clean beat that appears to have catalysed the current re-rating. The next scheduled report is July 29. Between now and then, the central question is whether the stock can hold its new multiple — or whether the shorts who stayed through a 31% rally will find their thesis validated as the momentum score continues rising alongside a valuation that offers less and less margin for error.
See the live data behind this article on ORTEX.
Open CORT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
